Company Profile

Targeson Inc (AKA: Targeson LLC)
Profile last edited on: 5/14/19      CAGE: 4KT90      UEI:

Business Identifier: Novel contrast agents for use in diagnosis and therapy of cardiovascular disease and tumor growth
Year Founded
2003
First Award
2007
Latest Award
2015
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3550 General Atomics Court MS 02-444
San Diego, CA 92121
   (858) 427-3675
   N/A
   www.targeson.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Targeson had een involved in development of ultrasound imaging agents for functional and molecular imaging applications in the research market. The firm's core technology platform used gas-encapsulated microspheres that when coated with specific targeting molecules can adhere to molecular markers of disease and then be imaged by ultrasound. This technique could be used in animal models of a wide variety of diseases, such as cancer, heart attack, atherosclerosis and cardiovascular plaque, organ transplant rejection, and inflammatory bowel disease. Initially targeted at the academic research market to generate income enabling the company to leverage the technology for a clinical product development program, the firm's commercial products included: Targestar® P, a non-targeted ultrasound contrast agent designed to enhance and quantify blood flow and vascular function; Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners; Targestar SA, a targetable ultrasound contrast agent enabling any biotinylated antibody or biomolecule to be coupled to a microsphere, making it suitable for a wide variety of molecular imaging applications including tumor angiogenesis, myocardial infarction, atherosclerotic plaque, thrombosis, organ transplant rejection and inflammatory diseases; Visistar® Integrin, a targeted ultrasound contrast agent coated with a peptide that binds integrin αvβ3; Visistar VEGFR2, a targeted ultrasound contrast agent coated with a VEGFR2 binding ligand, both indicated for molecular imaging of angiogenesis and tumor growth; Visistar VCAM-1, a targeted ultrasound contrast agent indicated for molecular imaging of inflammation; and Targesphere™, a delivery agent for transfection. As of mid 2017, the firm seems to have discontinued operat

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NIH $224,228
Project Title: Scalable Transfection Technology for Lymphocytes
2014 2 NIH $1,960,355
Project Title: Ultrasound-Based Molecular Imaging Probe for Imaging Acute Myocardial Syndromes
2014 1 NIH $225,000
Project Title: Molecular Imaging of Macrophage Infiltration in Solid Cancers
2012 2 NIH $1,533,707
Project Title: Ultrasound Mediated Targeted Therapy For Kidney Disease
2011 1 NIH $195,662
Project Title: Contrast Agents For High-Sensitivity Ultrasound Molecular Imaging Of Tumor Angiog

Key People / Management

  Jack Defranco -- President and Chief Executive Officer

  Joshua J Rychak -- Cofounder and VP Research and Development